Search Results

There are 12352 results for: content related to: Unilateral intraocular mastocytosis and anterior uveitis in a dog with subcutaneous mast cell tumors

  1. You have free access to this content
    Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 194–205, C. London, T. Mathie, N. Stingle, C. Clifford, S. Haney, M. K. Klein, L. Beaver, K. Vickery, D. M. Vail, B. Hershey, S. Ettinger, A. Vaughan, F. Alvarez, L. Hillman, M. Kiselow, D. Thamm, M. L. Higginbotham, M. Gauthier, E. Krick, B. Phillips, T. LaDue, P. Jones, J. Bryan, V. Gill, A. Novasad, L. Fulton, J. Carreras, C. McNeill, C. Henry and S. Gillings

    Version of Record online : 1 JUN 2011, DOI: 10.1111/j.1476-5829.2011.00275.x

  2. Kinase dysfunction and kinase inhibitors

    Veterinary Dermatology

    Volume 24, Issue 1, February 2013, Pages: 181–e40, Cheryl A. London

    Version of Record online : 19 JAN 2013, DOI: 10.1111/j.1365-3164.2012.01081.x

  3. You have free access to this content
    European consensus document on mast cell tumours in dogs and cats

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: e1–e29, L. Blackwood, S. Murphy, P. Buracco, J. P. De Vos, P. De Fornel-Thibaud, J. Hirschberger, M. Kessler, J. Pastor, F. Ponce, K. Savary-Bataille and D. J. Argyle

    Version of Record online : 6 AUG 2012, DOI: 10.1111/j.1476-5829.2012.00341.x

  4. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 174–183, C. Robat, C. London, L. Bunting, L. McCartan, N. Stingle, K. Selting, I. Kurzman and D. M. Vail

    Version of Record online : 31 JAN 2011, DOI: 10.1111/j.1476-5829.2011.00261.x

  5. Pharmacokinetic properties of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 33, Issue 2, April 2010, Pages: 162–171, M. F. YANCEY, D. A. MERRITT, S. P. LESMAN, J. F. BOUCHER and G. M. MICHELS

    Version of Record online : 8 MAR 2010, DOI: 10.1111/j.1365-2885.2009.01133.x

  6. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 163–173, S. Bavcar and D. J. Argyle

    Version of Record online : 6 AUG 2012, DOI: 10.1111/j.1476-5829.2012.00342.x

  7. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours

    Veterinary and Comparative Oncology

    Volume 8, Issue 3, September 2010, Pages: 209–220, E. K. Malone, K. M. Rassnick, J. J. Wakshlag, D. S. Russell, R. Al-Sarraf, D. M. Ruslander, C. S. Johnson and D. L. Trump

    Version of Record online : 24 JUN 2010, DOI: 10.1111/j.1476-5829.2010.00223.x

  8. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats

    Veterinary and Comparative Oncology

    Volume 15, Issue 3, September 2017, Pages: 710–717, C. H. Merrick, J. Pierro, S. E. Schleis, E. A. Sones, Z. M. Wright, R. C. Regan, C. T. Siedlecki and P. J. Bergman

    Version of Record online : 4 APR 2016, DOI: 10.1111/vco.12211

  9. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study

    Veterinary and Comparative Oncology

    Volume 10, Issue 3, September 2012, Pages: 184–193, E. Chon, L. McCartan, L. N. Kubicek and D. M. Vail

    Version of Record online : 21 MAR 2011, DOI: 10.1111/j.1476-5829.2011.00265.x

  10. PRELIMINARY EVALUATION OF SERIAL 18FDG-PET/CT TO ASSESS RESPONSE TO TOCERANIB PHOSPHATE THERAPY IN CANINE CANCER

    Veterinary Radiology & Ultrasound

    Volume 53, Issue 3, May/June 2012, Pages: 348–357, Amy K. LeBlanc, Ashley N. Miller, Gina D. Galyon, Tamberlyn D. Moyers, Misty J. Long, Alan C. Stuckey, Jonathan S. Wall and Federica Morandi

    Version of Record online : 24 FEB 2012, DOI: 10.1111/j.1740-8261.2012.01925.x

  11. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study

    Veterinary and Comparative Oncology

    Volume 15, Issue 3, September 2017, Pages: 919–931, M. A. Pellin, R. M. Wouda, K. Robinson, K. Tsimbas, I. D. Kurzman, B. J. Biller and D. M. Vail

    Version of Record online : 5 MAY 2016, DOI: 10.1111/vco.12232

  12. Advances in the management of skin cancer

    Veterinary Dermatology

    Volume 24, Issue 1, February 2013, Pages: 173–e38, Pamela D. Martin and David J. Argyle

    Version of Record online : 19 JAN 2013, DOI: 10.1111/j.1365-3164.2012.01107.x

  13. You have full text access to this Open Access content
    Clinical and Immunomodulatory Effects of Toceranib Combined with Low-Dose Cyclophosphamide in Dogs with Cancer

    Journal of Veterinary Internal Medicine

    Volume 26, Issue 2, March-April 2012, Pages: 355–362, L. Mitchell, D.H. Thamm and B.J. Biller

    Version of Record online : 4 FEB 2012, DOI: 10.1111/j.1939-1676.2011.00883.x

  14. Distribution, metabolism, and excretion of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 33, Issue 2, April 2010, Pages: 154–161, M. F. YANCEY, D. A. MERRITT, J. A. WHITE, S. A. MARSH and C. W. LOCUSON

    Version of Record online : 8 MAR 2010, DOI: 10.1111/j.1365-2885.2009.01120.x

  15. You have full text access to this Open Access content
    Multicenter Prospective Trial of Hypofractionated Radiation Treatment, Toceranib, and Prednisone for Measurable Canine Mast Cell Tumors

    Journal of Veterinary Internal Medicine

    Volume 26, Issue 1, January-February 2012, Pages: 135–141, K.S. Carlsten, C.A. London, S. Haney, R. Burnett, A.C. Avery and D.H. Thamm

    Version of Record online : 19 DEC 2011, DOI: 10.1111/j.1939-1676.2011.00851.x

  16. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study

    Veterinary and Comparative Oncology

    Volume 16, Issue 1, March 2018, Pages: E52–E60, R. M. Wouda, S. E. Hocker and M. L. Higginbotham

    Version of Record online : 10 AUG 2017, DOI: 10.1111/vco.12332

  17. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours

    Veterinary and Comparative Oncology

    Volume 8, Issue 2, June 2010, Pages: 138–152, K. M. Rassnick, D. B. Bailey, D. S. Russell, A. B. Flory, M. A. Kiselow, J. L. Intile, E. K. Malone, C. E. Balkman and S. M. Barnard

    Version of Record online : 17 MAY 2010, DOI: 10.1111/j.1476-5829.2010.00217.x

  18. You have full text access to this OnlineOpen article
    Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs

    Journal of Veterinary Internal Medicine

    Volume 32, Issue 1, January/February 2018, Pages: 377–383, K.R. Hume, V.L. Rizzo, J.R. Cawley and C.E. Balkman

    Version of Record online : 30 NOV 2017, DOI: 10.1111/jvim.14882

  19. You have full text access to this OnlineOpen article
    2016 ACVIM Forum Research Abstract Program

    Journal of Veterinary Internal Medicine

    Volume 30, Issue 4, July/August 2016, Pages: 1407–1519,

    Version of Record online : 31 MAY 2016, DOI: 10.1111/jvim.13952

    Corrected by:

    Erratum: Erratum

    Vol. 31, Issue 1, 272, Version of Record online: 24 JAN 2017

  20. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia®) in tumour-bearing dogs: a phase I dose-finding study

    Veterinary and Comparative Oncology

    Volume 14, Issue 2, June 2016, Pages: 202–209, X. Pan, K. Tsimbas, I. D. Kurzman and D. M. Vail

    Version of Record online : 15 APR 2014, DOI: 10.1111/vco.12091